Andrew Heyward, Ragen MacKenzie. The rating is based on the stock's high valuation. Mark Augustine, U.S. Bancorp Piper Jaffray. Gerard Feenan, Value Line. Enbrel sales should grow rapidly.
Prospects remain excellent, but price is extremely rich.
Lucien Virgile, Value Line. Company has prospects, but these shares remain speculative. Several coming events could rekindle enthusiasm. Warning blurs visibility, depresses stock price. But long-term initiatives are proceeding.